Resonetics

Executive Summary

Resonetics is a global leader in advanced engineering, prototyping, and micro-manufacturing for the medical device and life sciences industries. The company specializes in high-precision manufacturing, particularly in Nitinol processing and microfluidic technologies, and collaborates with MedTech partners to accelerate the development and commercialization of breakthrough medical devices, diagnostics, and drug delivery systems. Founded in 1987 and headquartered in Nashua, New Hampshire (with operations also noted in Switzerland), Resonetics serves a critical role in the supply chain for minimally invasive devices and drug-eluting implants. Its deep expertise in Nitinol shape memory alloys and micro-scale components positions it well to benefit from secular trends toward less invasive procedures and advanced drug delivery. While the company is privately held and does not disclose financials, its long track record and established relationships with major medical device firms suggest a stable revenue base. Growth catalysts include increasing R&D spend by MedTech clients, expansion into new therapeutic areas like neurology and ophthalmology, and potential capacity expansions to meet demand. However, lack of public market disclosure limits conviction. The private company status and absence of recent funding rounds or public milestones reduce visibility, making it a moderate-conviction investment thesis.

Upcoming Catalysts (preview)

• Q3 2026Major MedTech partnership or contract win for Nitinol components in next-gen structural heart or neurovascular devices70% success
• Q4 2026Facility expansion or new manufacturing line announcement to meet rising demand for microfluidics in diagnostics60% success
• Q1 2027FDA approval of a key client device utilizing Resonetics' micro-manufacturing, triggering follow-on orders50% success